DIFFERENCES IN SIDE-EFFECTS OF AMANTADINE HYDROCHLORIDE AND RIMANTADINE HYDROCHLORIDE RELATE TO DIFFERENCES IN PHARMACOKINETICS
DIFFERENCES IN SIDE-EFFECTS OF AMANTADINE HYDROCHLORIDE AND RIMANTADINE HYDROCHLORIDE RELATE TO DIFFERENCES IN PHARMACOKINETICS
复制标题
DOI:
10.1128/aac.23.3.458
复制
发表时间:
1983-01-01
影响因子:
4.9
通讯作者:
SPYKER, DA
中科院分区:
文献类型:
--
作者:
HAYDEN, FG;HOFFMAN, HE;SPYKER, DA
In a double-blind, placebo-controlled study, the comparative toxicities and blood concentrations of amantadine hydrochloride and rimantadine hydrochloride were determined. Healthy, working adults ingested 200 (n = 52) or 300 mg (n = 196)/day in divided doses for 4.5 days. Mean plasma drug concentrations at 4 h after the 1st dose were lower in rimantadine recipients given 100- (140 vs. 300 ng/ml for rimantadine and amantadine, respectively; P < 10-5) or 200-mg doses (310 vs. 633 ng/ml; P < 10-5). The plasma drug concentrations after the 1st dose correlated significantly with total symptom sources for amantadine and rimantadine; the plasma levels of intoxicated and non-intoxicated subjects overlapped extensively. At 300 mg/day dosage, amantadine was associated more often with adverse CNS symptoms (33% of amantadine vs. 9% of rimantadine recipients; P < 0.001) and sleep disturbance (39 vs. 13%; P < 0.001), but not gastrointestinal symptoms (19.5 vs. 16.0%). No differences between the drugs were noted in symptom frequency or scores in volunteers with similar plasma concentrations. Amantadine and rimantadine differ in their pharmacokinetics, but not in their potential for side effects at comparable plasma concentrations.